Related Experiment Video
Updated: Jan 29, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
4.1K
Renal Artery Denervation for Hypertension
Lauren S Ranard1, Rajesh V Swaminathan2,3
1Duke University Medical Center, 2301 Erwin Rd, Durham, NC, 27710, USA. las104@duke.edu.
Current Treatment Options in Cardiovascular Medicine
|February 15, 2019
Summary
Renal denervation (RDN) is a promising therapy for resistant hypertension by targeting the sympathetic nervous system (SNS). While past trials faced challenges, ongoing research and innovative technology show potential for RDN
Area of Science:
- Cardiology
- Nephrology
- Medical Technology
Background:
- Hypertension (HTN) affects over 1 billion people globally, with 2-16% experiencing resistant HTN.
- The sympathetic nervous system (SNS) plays a key role in resistant HTN pathophysiology.
- Current pharmacotherapies inadequately target the SNS, making it a focus for new treatments.
Purpose of the Study:
- To review the evidence and rationale for renal denervation (RDN) therapy.
- To discuss the available technologies for RDN.
- To explore the role of SNS modulation in resistant hypertension.
Main Methods:
- Review of clinical trial data and scientific literature on RDN.
- Analysis of the impact of the SYMPLICITY HTN-3 trial.
- Examination of ongoing research and technological advancements in RDN.
Main Results:
- Early trials indicated RDN's effectiveness for resistant hypertension.
- The SYMPLICITY HTN-3 trial's failure prompted further investigation into RDN.
- Subsequent SPYRAL program trials showed controlled efficacy, though underpowered.
- Current data has limitations and potential biases, necessitating continued research.
- Contemporary studies and ongoing innovation are promising for RDN applications.
Conclusions:
- RDN therapy holds potential for managing resistant hypertension by targeting the SNS.
- Continued research, patient selection refinement, and device innovation are critical.
- Future trials are essential to fully establish the clinical utility of RDN.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
595
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
595
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
464
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
464
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
495
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
495
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
612
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
612
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
518
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
518
01:28Hypertension I: Introduction
848
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
848